According to a report, Boston Scientific is considering taking over Shockwave Medical, causing SWAV stock to soar. Shockwave Medical uses electrical impulses to “crack” hardened calcium in the arteries through a process called intravascular lithotripsy. This process is becoming increasingly popular as an alternative to atherectomy, which uses a small drill to remove calcifications. The potential deal could strengthen Boston Scientific’s cardiovascular portfolio, which generated over $7.8 billion in sales last year.
The available market for intravascular lithotripsy is worth about $8.5 billion, and Shockwave’s technology provides three new higher-paying codes for the procedure. SWAV stock is highly rated, with a strong Composite Rating of 98 and a Relative Strength Rating of 94.
